Multiple Myeloma Committee Meeting Agenda

Chair: Paul Richardson, MD
Vice-Chairs: Philip McCarthy, MD

I. Welcome and Introductions

II. Alliance Studies (Completed and Ongoing)
   a. A061202: Phase I/II Pom/Dex +/- Ixazomib (MLN9708) in Relapsed and Refractory MM (RR MM) – Peter Voorhees
   b. A061402: Solitary Osseous Plasmacytoma – Anuj Mahindra
   c. AFT29: Phase II RVd +/- Dara (the Griffin trial) in Newly Diagnosed (ND) MM – Peter Voorhees, Jacob Laubach, Paul Richardson
   d. CALGB 100104 Phase III and derived studies – Phil McCarthy
   e. Auto/Allo in MM (CALGB 100001; Phase I/II) - Phil McCarthy
   f. IFM/DFCI 2009 Study (Phase III BMT CTN 1304; the Determination trial) – Paul Richardson
   g. AFT15: Phase I/II Ibrutinib + Rd in RR MM – Yvonne Efebera & Jacob Laubach

III. Alliance Studies (Activation Pending)
   a. AFT41: Phase II RID +/- Dara in non-SCT eligible ND MM – Betsy O’Donnell, Jacob Laubach, Paul Richardson, Noopur Raje

III. Endorsed Studies
   a. ECOG – E1A11: Phase III RVd vs KRd in ND MM – Edward Faber
b. ECOG – E3A06: Phase III Smoldering Myeloma (lenalidomide vs placebo) – Anuj Mahindra

c. SWOG – S1211: Phase III RVd +/- Elo for ND high risk MM – Peter Voorhees

d. SWOG – S1304: Phase II Carfilzomib in RR MM (completed; results pending) – Peter Voorhees

e. BMT CTN 1302: Phase II RIC Allo-SCT followed by Ixazomib maintenance in ND MM – Cristina Gasparetto

f. SWOG – S1702: Phase II Isatuximab for previously treated AL Amyloidosis – Heather Landau & Hani Hassoun

IV. **New Initiatives in Process**

a. AFT35: Phase I/II PVd Dara in RR MM – Hani Hassoun, Paul Richardson

b. A061901: Phase I/II study of Venetoclax w/ RVD + Dara in newly-diagnosed plasma cell leukemia – Peter Voorhees

c. A061902: Maintenance after 2nd transplant with Venetoclax – Sarah Holstein and Phil McCarthy

V. **New Proposals in Development**

a. Rev +/- ACY241 S/PASCT – Sarah Holstein & Philip McCarthy

b. Optimal duration of lenalidomide maintenance in MRD negative ND MM patients post ASCT – Peter Voorhees

c. Phase II study of CyBorD-Dara in monoclonal gammopathy-associated kidney diseases – Hani Hassoun, Sasha Tuchman, Anuj Mahindra, Giada Bianchi

VI. **Correlative Science Studies**

a. A151210/ A151211: Understanding the molecular basis for myeloid B-cell transformation in the plasma cell dyscrasias and second malignancies in myeloma – Phil McCarthy

b. Therapeutic Subcommittee for MM in Older Adults – Tanya Wildes, Sascha Tuchman, Ashley Rosko, Betsy O'Donnell

VII. **Closing Remarks**